A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model

References

• Celebrex® Product Information. Kansas: Pfizer, Inc., 2010. http://www.celebrex.com. Accessed September 19, 2012
   Google Scholar
• Pfizer AB 191 90 Sollentuna. Swedish Celebrex Summary of Product Characteristics. http://www.fass.se/LIF/produktfakta/artikel_produkt.jsp?NplID=20101030000078&DocTypeID=6. Accessed September 19, 2012
   Google Scholar
• Jonsson D, Husberg M. (1995). Samhallsekonomiska kostnader for reumatiska sjukdomar. Linköping, Sweden: Linköping University; CMT Rapport; 5
   Google Scholar
• National Collaborating Centre for Chronic Conditions. Osteoarthritis: national clinical guidelines for care and management in adults. London: Royal College of Physicians, 2008. http://www.nice.org.uk/nicemedia/live/11926/39720/39720.pdf, Accessed September 19, 2012
   Google Scholar
• Tarone RE, Blot WJ, McLaughlin JK. Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am J Ther 2004;11:17-25
   PubMedGoogle Scholar
• National Institute for Health and Clinical Excellence. http://www.nice.org.uk. Accessed January 27, 2011
   Google Scholar
• McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cart 2014;22:363-88
   PubMed Web of Science ®Google Scholar
• Latimer N, Lord J, Grant RL, et al. National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ 2009;339:b2538
   Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55
   PubMed Web of Science ®Google Scholar
• Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771-81
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74
   PubMed Web of Science ®Google Scholar
• Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med 2006;119:255-66
   PubMed Web of Science ®Google Scholar
• Wilson I, Langstrom G, Wahlqvist P, et al. Management of gastroduodenal ulcers and gastrointestinal symptoms associated with nonsteroidal anti-inflammatory drug therapy: a summary of four comparative trials with omeprazole, ranitidine, misoprostol, and placebo. Curr Ther Res 2001;62:835-50
   Google Scholar
• Appendix D, National Collaborating Centre for Chronic Conditions. Osteoarthritis: national clinical guidelines for care and management in adults. London: Royal College of Physicians, 2008. http://www.nice.org.uk/nicemedia/live/11926/39720/39720.pdf. Accessed January 27, 2011
   Google Scholar
• Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheumatis 2003;49:283-92
   PubMedGoogle Scholar
• Pickard A, Johnson JA, Feeny DH. Responsiveness of generic health-related quality of life measures in stroke. Quality Life Res 2005;14:207-19
   PubMed Web of Science ®Google Scholar
• Tandvårds- ochläkemedelsförmånsverket – Dental and Pharmaceutical Benefits Board. Price Database. Stockhold: TLV. http://www.tlv.se/in-english-old/price-database. Accessed June 24, 2010
   Google Scholar
• Stockholm County Council. Treatment guidelines. Stockholm: Vårdinformation StorStockholm, 2010. http://www.viss.nu. Accessed August 30, 2010
   Google Scholar
• Region Skånes primärvård. Region price list. Lund: Södra Regionvårdsnämnden, 2010. http://www.skane.se. Accessed August 30, 2010
   Google Scholar
• The Swedish National Inpatient Register (Slutenvårdsregistret). http://www.sos.se. Accessed August 30, 2010
   Google Scholar
• Zethraeus N, Molin T, Henriksson P, et al. Cost of coronary heart disease and stroke: the case of Sweden. J Intern Med 1999;246:151-9
   PubMed Web of Science ®Google Scholar
• Statistiska centralbyrå. Consumer price index Stockholm: Statistiska centralbyrå, 2008. http://www.scb.se. Accessed January 27, 2011
   Google Scholar